915 abstracts found.



Results filter

C3

Year:

Session type:

Promoting early presentation of breast cancer: implementation and evaluation of a training programme for radiographers to deliver a psycho-educational intervention

Caroline Burgess1, Patsy Whelehan2, Lynne Omar1, Lorraine Tucker1, Amanda Ramirez1

Targeting invasion and metastasis

Year:

Session type:

Margaret Frame

Beatson Institute for Cancer Research, Glasgow, UK

Exploring chemical and biological space: new approaches to drug discovery in oncology

Year:

Session type:

Sir Tom Blundell

University of Cambridge, UK

How much do age, clinical and psychological factors contribute to fatigue following radiotherapy for early breast cancer? Evidence from the START Trials (UK Standardisation of Breast Radiotherapy)

Year:

Session type:

Judith Mills1, Georges Sumo1, Joanne Haviland1, Judith Bliss1, Penelope Hopwood2, on behalf of the START Trial Management Group1

1ICR-CTSU, The Institute of Cancer Research, Sutton, UK, 2Psycho-oncology Services, Christie Hospital NHS Foundation Trust, Manchester, UK

ERK-MAP kinase signalling: biological context, cellular location, signal strength and duration dictate cell fate

Year:

Session type:

John Blenis

Harvard Medical School, Boston, USA

Structure-function and structure-inhibition relationships in the CDK family

Year:

Session type:

Martin Noble

University of Oxford, UK

Addressing delayed cancer diagnosis in primary care: Patterns of attendance and symptoms of teenagers and young adults seen in 3 general practices during 1 year

Year:

Session type:

Lorna Fern1, Christine Campbell2, Tim Eden3, Robert Grant4, Ian Lewis5, Una McLeod6, David Weller2, Jeremy Whelan1

1University College Hospitals, London, UK, 2University of Edinburgh, Edinburgh, UK, 3University of Manchester, Manchester, UK, 4St Brysdale Surgery, Fife, UK, 5University of Leeds, Leeds, UK, 6University of Glasgow, Glasgow, UK

C-Met oncogenic mutants sustain signals in the endosome and are protected against downregulation

Year:

Session type:

Carine Joffre, Stephanie Kermorgant

Institute of Cancer and Cancer Research UK Clinical Centre, Bart's and The London School of Medicine and Dentistry, London, UK

Identifying the next generation of anticancer drug targets

Year:

Session type:

Bob Jackson

Pharmacometrics Ltd, Cambridge, UK

Telomerase-based immunotherapy of cancer

Year:

Session type:

Robert Vonderheide

University of Pennsylvania, Philadelphia, USA

Cross talk between the VEGF and Notch signalling pathways in endothelial cells

Year:

Session type:

Laura Harrington, Richard Sainson, Chern Ein Oon, Helen Sheldon, Ji-Liang Li, Adrian Harris

Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK

Isoindolinone inhibitors of the MDM2-p53 protein-protein interaction: structure-activity studies

Year:

Session type:

Anna Watson, Eric Valeur, Bernard Golding, Roger Griffin, Claire Hutton, Jungfeng Liu, Xiaohong Lu, John Lunec, David Newell, Ian Hardcastle

Northern Institute for Cancer Research, Newcastle upon Tyne, UK

DNA fusion gene vaccination, delivered with or without in vivo electroporation – a potent and safe strategy for inducing anti-tumour immune responses in prostate cancer

Year:

Session type:

Christian Ottensmeier

University of Southampton, UK

Lysyl oxidase secreted by hypoxic tumour cells is critical for pre-metastatic niche formation

Year:

Session type:

Janine Erler1, Kevin Bennewith2, Amato Giaccia2

1Institute of Cancer Research, London, UK, 2Stanford University, California, USA

A novel small molecule inhibits cancer cell proliferation in vitro and in vivo via activation of the protein kinase AMPK

Year:

Session type:

Hakim Djeha1, Björn Eriksson2, Thomas Edlund2, Fiona McLaughlin1

1Antisoma Research Ltd, Welwyn Garden City, Herts, UK, 2Betagenon AB, Umeå, Sweden